- Home
- ABL vs MGTX Comparison
ABL vs MGTX Comparison
Compare ABL & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- MGTX
- Stock Information
- Founded
- ABL 2004
- MGTX 2015
- Country
- ABL United States
- MGTX United States
- Employees
- ABL N/A
- MGTX N/A
- Industry
- ABL Investment Managers
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABL Finance
- MGTX Health Care
- Exchange
- ABL Nasdaq
- MGTX Nasdaq
- Market Cap
- ABL 521.6M
- MGTX 520.8M
- IPO Year
- ABL N/A
- MGTX N/A
- Fundamental
- Price
- ABL $4.93
- MGTX $8.47
- Analyst Decision
- ABL Strong Buy
- MGTX Strong Buy
- Analyst Count
- ABL 4
- MGTX 2
- Target Price
- ABL $13.13
- MGTX $24.00
- AVG Volume (30 Days)
- ABL 1.2M
- MGTX 541.8K
- Earning Date
- ABL 08-11-2025
- MGTX 08-11-2025
- Dividend Yield
- ABL N/A
- MGTX N/A
- EPS Growth
- ABL N/A
- MGTX N/A
- EPS
- ABL N/A
- MGTX N/A
- Revenue
- ABL $134,575,948.00
- MGTX $34,508,000.00
- Revenue This Year
- ABL $68.84
- MGTX $365.04
- Revenue Next Year
- ABL $26.84
- MGTX $73.18
- P/E Ratio
- ABL N/A
- MGTX N/A
- Revenue Growth
- ABL 73.39
- MGTX 203.23
- 52 Week Low
- ABL $4.60
- MGTX $3.85
- 52 Week High
- ABL $11.86
- MGTX $8.75
- Technical
- Relative Strength Index (RSI)
- ABL 32.48
- MGTX 76.43
- Support Level
- ABL $5.06
- MGTX $6.31
- Resistance Level
- ABL $5.68
- MGTX $8.75
- Average True Range (ATR)
- ABL 0.30
- MGTX 0.45
- MACD
- ABL 0.06
- MGTX 0.19
- Stochastic Oscillator
- ABL 30.12
- MGTX 89.55
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.